Dr. Berchuck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1364 Clifton Rd NE
Atlanta, GA 30322Phone+1 404-778-1900Fax+1 617-632-2165
Summary
- Dr. Jacob Berchuck is a Medical Oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber/Brigham and Women's Cancer Center. Dr. Berchuck received his undergraduate and medical degrees from Duke University, trained in Internal Medicine at the University of California San Francisco, and completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. In addition to caring for patients with prostate, kidney, bladder, and testicular cancer, Dr. Berchuck conducts research using cell-free DNA to develop "liquid biopsies" for early and accurate cancer detection.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
University of California (San Francisco)Residency, Internal Medicine, 2013 - 2016
Duke University School of MedicineClass of 2013
Certifications & Licensure
MA State Medical License 2017 - 2026
GA State Medical License 2024 - 2025
CA State Medical License 2014 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsCo-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.Jacob J Orme, Fadi Taza, Navonil De Sarkar, Alok K Tewari, Syed Arsalan Naqvi
European Urology Oncology. 2024-08-01 - 29 citationsDifferential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, Hao Wang, Nabil Adra
JCO Precision Oncology. 2021-07-22 - 65 citationsReprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Sylvan C. Baca, David Y. Takeda, Ji-Heui Seo, Justin H. Hwang, Sheng-Yu Ku
Nature Communications. 2021-03-30
Press Mentions
Addressing Mental Health in Patients with Lung Cancer Improves OutcomesJuly 30th, 2022- Research Round-up: Lung CancerNovember 18th, 2020
ASCO GU 2020: Best of Journals Prostate Cancer: SurgeryFebruary 17th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
